Top-line results from a phase III study of Aldeyra Therapeutics Inc.'s aldehyde-trapping reproxalap in allergic conjunctivitis showed two different concentrations of the drug driving statistically significant reductions in ocular itching vs. placebo. The outcome, which carried company shares (NASDAQ:ALDX) 36 percent higher to $9.71 Tuesday, put Aldeyra on track to advance what president and CEO Todd Brady said could potentially provide a new treatment option for the third of people who, without gaining relief from antihistamines, have to resort to topical corticosteroids. Once the company consults with regulators, another phase III study in allergic conjunctivitis could start as soon as the second half of this year.